Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Mitral Valve Prolapse I: Introduction

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Meiosis vs. Mitosis

Meiosis vs. Mitosis

Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...

Mechanism of Cardiac Arrhythmias

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is Mirtazapine an Effective Treatment for Nausea and Vomiting of Pregnancy?: A Case Series.

Journal of clinical psychopharmacology·2017

Same author

Prenatal Antidepressant Use and Risk of Autism Spectrum Disorders in Children.

JAMA pediatrics·2016

Same author

Antidepressant use in pregnancy: knowledge transfer and translation of research findings.

Journal of evaluation in clinical practice·2015

Same author

Developmental risks associated with use of psychoactive drugs during pregnancy are largely unknown. Authors' reply.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·2014

Same author

Antidepressant use in pregnancy: an evaluation of adverse outcomes excluding malformation.

The Israel journal of psychiatry and related sciences·2014

Same author

Health literacy and its association with perception of teratogenic risks and health behavior during pregnancy.

Patient education and counseling·2014

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Does paroxetine cause cardiac malformations?

Lisa O'Brien¹, Thomas R Einarson², Moumita Sarkar¹

¹The Motherisk Program, The Hospital for Sick Children, Toronto, Toronto ON; Institute of Medical Science, University of Toronto, Toronto ON.

Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC

|September 13, 2008

Summary

This summary is machine-generated.

Paroxetine use during pregnancy is not linked to higher cardiac defect risks. This meta-analysis of nine studies offers reassurance for women needing this medication during pregnancy.

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Using Immunofluorescence to Detect PM2.5-induced DNA Damage in Zebrafish Embryo Hearts

Using Immunofluorescence to Detect PM_2.5-induced DNA Damage in Zebrafish Embryo Hearts

Published on: February 15, 2021

Related Experiment Videos

Last Updated: Jul 1, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Using Immunofluorescence to Detect PM2.5-induced DNA Damage in Zebrafish Embryo Hearts

Using Immunofluorescence to Detect PM_2.5-induced DNA Damage in Zebrafish Embryo Hearts

Published on: February 15, 2021

Area of Science:

Pharmacovigilance
Reproductive Toxicology
Clinical Epidemiology

Background:

Recent concerns regarding paroxetine safety in pregnancy due to potential cardiac defect risks.
Reports suggest increased risks following first-trimester exposure to paroxetine.

Purpose of the Study:

To evaluate the association between first-trimester paroxetine exposure and cardiac malformations.
To provide evidence-based information for healthcare providers and pregnant women regarding paroxetine safety.

Main Methods:

A meta-analysis was performed, synthesizing data from nine distinct studies.
Included studies comprised three case-control and six cohort study designs.

Main Results:

Case-control studies (N=30,247) showed no increased risk of congenital malformations (OR=1.18; 95% CI 0.88-1.59).
Cardiac malformation rates were comparable between exposed and unexposed groups (1.1%) and within population norms (0.7-1.2%).
Cohort studies (N=66,409) indicated a non-significant weighted average difference of 0.3% (95% CI -0.1-0.7%; P=0.19).

Conclusions:

First-trimester paroxetine exposure is not associated with elevated cardiac malformation rates.
Findings suggest paroxetine can be safely prescribed to pregnant women requiring treatment.
This evidence should alleviate concerns for physicians and patients regarding paroxetine use in pregnancy.